姜 紹青

Medicine & Life Sciences

1. Taiwan 100%
2. Drug Therapy 54%
3. Guidelines 44%
4. Breast Neoplasms 43%
5. Antineoplastic Agents 34%
6. Pharmaceutical Preparations 33%
7. National Health Programs 33%
8. Granulocyte Colony-Stimulating Factor 32%
9. Neutropenia 27%
10. Chemotherapy-Induced Febrile Neutropenia 24%
11. Pharmacists 21%
12. Medication Systems 20%
13. Medication Reconciliation 20%
14. pazopanib 20%
15. Biosimilar Pharmaceuticals 19%
16. Pharmacy 17%
17. Psychological Handling 17%
18. Cost-Benefit Analysis 16%
19. Practice Management 16%
20. Delivery of Health Care 14%
21. Cohort Studies 13%
22. Renal Cell Carcinoma 13%
23. Neoplasms 12%
24. Non-Hodgkin's Lymphoma 12%
25. Equipment and Supplies 12%
26. Health Care Costs 12%
27. Sunitinib 11%
28. Physicians 11%
29. Risk Assessment 11%
30. Health 11%
31. Personal Protective Equipment 10%
32. Medication Errors 8%
33. Occupational Health 8%
34. Drug Compounding 8%
35. Safety 8%
36. Drug Storage 8%
37. Waste Management 7%
38. Expert Testimony 7%
39. Nursing Societies 6%
40. Occupational Groups 6%
41. Febrile Neutropenia 6%
42. Drug-Related Side Effects and Adverse Reactions 6%
43. Visual Analog Scale 6%
44. Oncology Nursing 5%
45. Placebo Effect 5%
46. Colorectal Surgery 5%
47. Patient Transfer 5%
48. Health Personnel 5%
49. Costs and Cost Analysis 5%